SUN PHARMA ADV. RES. | SUYOG TELEMATICS | SUN PHARMA ADV. RES./ SUYOG TELEMATICS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -26.6 | 9.4 | - | View Chart |
P/BV | x | - | 3.0 | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA ADV. RES. Mar-21 |
SUYOG TELEMATICS Mar-21 |
SUN PHARMA ADV. RES./ SUYOG TELEMATICS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 210 | 549 | 38.2% | |
Low | Rs | 95 | 247 | 38.3% | |
Sales per share (Unadj.) | Rs | 9.7 | 129.9 | 7.4% | |
Earnings per share (Unadj.) | Rs | -5.8 | 24.0 | -24.0% | |
Cash flow per share (Unadj.) | Rs | -5.4 | 39.5 | -13.5% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -6.4 | 129.3 | -5.0% | |
Shares outstanding (eoy) | m | 262.05 | 10.15 | 2,581.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 15.8 | 3.1 | 514.1% | |
Avg P/E ratio | x | -26.4 | 16.6 | -159.3% | |
P/CF ratio (eoy) | x | -28.4 | 10.1 | -282.3% | |
Price / Book Value ratio | x | -23.7 | 3.1 | -769.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 39,871 | 4,040 | 986.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 916 | 190 | 481.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,530 | 1,318 | 191.9% | |
Other income | Rs m | 54 | 27 | 198.1% | |
Total revenues | Rs m | 2,584 | 1,345 | 192.1% | |
Gross profit | Rs m | -1,350 | 656 | -205.8% | |
Depreciation | Rs m | 109 | 157 | 69.5% | |
Interest | Rs m | 107 | 104 | 102.5% | |
Profit before tax | Rs m | -1,511 | 422 | -357.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 178 | 0.0% | |
Profit after tax | Rs m | -1,511 | 244 | -619.4% | |
Gross profit margin | % | -53.4 | 49.8 | -107.2% | |
Effective tax rate | % | 0 | 42.2 | 0.0% | |
Net profit margin | % | -59.7 | 18.5 | -322.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 631 | 776 | 81.3% | |
Current liabilities | Rs m | 2,334 | 882 | 264.7% | |
Net working cap to sales | % | -67.3 | -8.0 | 842.3% | |
Current ratio | x | 0.3 | 0.9 | 30.7% | |
Inventory Days | Days | 111 | 56 | 200.2% | |
Debtors Days | Days | 254 | 74,281,841 | 0.0% | |
Net fixed assets | Rs m | 1,666 | 2,356 | 70.7% | |
Share capital | Rs m | 262 | 102 | 258.1% | |
"Free" reserves | Rs m | -1,945 | 1,211 | -160.6% | |
Net worth | Rs m | -1,683 | 1,312 | -128.2% | |
Long term debt | Rs m | 1,167 | 298 | 391.8% | |
Total assets | Rs m | 2,297 | 3,135 | 73.3% | |
Interest coverage | x | -13.2 | 5.1 | -260.4% | |
Debt to equity ratio | x | -0.7 | 0.2 | -305.5% | |
Sales to assets ratio | x | 1.1 | 0.4 | 262.0% | |
Return on assets | % | -61.2 | 11.1 | -551.3% | |
Return on equity | % | 89.8 | 18.6 | 483.0% | |
Return on capital | % | 272.6 | 32.7 | 834.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 120 | 0 | - | |
Fx outflow | Rs m | 2,141 | 0 | - | |
Net fx | Rs m | -2,021 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,519 | 469 | -324.2% | |
From Investments | Rs m | 16 | -448 | -3.5% | |
From Financial Activity | Rs m | 1,593 | -55 | -2,903.5% | |
Net Cashflow | Rs m | 90 | -35 | -258.1% |
Indian Promoters | % | 69.1 | 48.1 | 143.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.2 | 0.0 | - | |
FIIs | % | 2.4 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 30.9 | 51.9 | 59.6% | |
Shareholders | 94,494 | 1,913 | 4,939.6% | ||
Pledged promoter(s) holding | % | 2.2 | 7.9 | 27.5% |
Compare SUN PHARMA ADV. RES. With: VA TECH WABAG SIS DELTA CORP BLS INTERNATIONAL SERVICES SYNGENE INTERNATIONAL
On Tuesday, Indian share markets ended on a firm note as fag-end buying in Reliance Industries and other index heavyweight stocks pushed benchmark indices higher.